GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Research & Development

Contineum Therapeutics (Contineum Therapeutics) Research & Development : $15.79 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Contineum Therapeutics's Research & Development for the three months ended in Mar. 2024 was $7.78 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $15.79 Mil.


Contineum Therapeutics Research & Development Historical Data

The historical data trend for Contineum Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Research & Development Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Research & Development
22.36 16.89 27.60

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial 3.95 3.63 - 8.01 7.78

Contineum Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Contineum Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus